Stocks in News: Kinross (NYSE:KGC), Blonder Tongue Laboratories (NYSEMKT: BDR), Akebia Therapeutics (NASDAQ:AKBA), Rofin-Sinar (NASDAQ:RSTI), CarMax (NYSE:KMX)

Gold miner Kinross Gold Corporation (NYSE:KGC) posted adjusted earnings of $32.9 million or 3 cents per share in the second quarter of 2014, down 72.5% from adjusted earnings of $119.5 million or 10 cents per share in the year-ago quarter. Earnings per share also missed the Zacks Consensus Estimate of 4 cents per share. Kinross Gold Corporation (NYSE:KGC) belongs to Basic Materials sector. Its weekly performance is -3.40%. On last trading day company shares ended up $3.98. Kinross Gold Corporation (NYSE:KGC) distance from 50-day simple moving average (SMA50) is -2.58%.

On June 16, 2014, the Board of Directors of Blonder Tongue Laboratories Inc. (NYSEMKT: BDR) adopted the Executive Stock Purchase Plan (the “Plan”). The Plan allows executive officers of the Company to elect to purchase common stock of the Company in lieu of receiving their salary. The maximum number of shares of common stock that can be purchased by all participants, in the aggregate, pursuant to the Plan is 250,000 shares. The shares will be purchased directly from the Company at the fair market value of the Company’s common stock on the date of purchase (based on selling prices reported on NYSE MKT), which is the payroll date when the salary is withheld. Blonder Tongue Laboratories Inc. (NYSEMKT: BDR) shares remains unchanged in last trading session and ended the day at $0.90. BDR Gross Margin is 32.20% and its return on assets is -15.80%. Blonder Tongue Laboratories Inc. (NYSEMKT: BDR) quarterly performance is 0.00%.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) a biopharmaceutical company focused on harnessing the potential of hypoxia-inducible factor (HIF) biology to develop and commercialize novel therapeutics to treat kidney disease, today announced that Michael D. Clayman, M.D., Chief Executive Officer of Flexion Therapeutics, Inc., and Maxine Gowen, Ph.D., President and Chief Executive Officer of Trevena, Inc., have been appointed to the Company’s Board of Directors. In addition, Kim L. Dueholm, Ph.D. will be stepping down from the Board on July 28, 2014, the effective date of Dr. Clayman and Dr. Gowen’s appointments. On 01 August, Akebia Therapeutics, Inc. (NASDAQ:AKBA) shares fell -3.16% and was closed at $21.44. AKBA EPS growth in last 5 year was 0.00%. Akebia Therapeutics, Inc. (NASDAQ:AKBA) year to date (YTD) performance is -19.67%.

Rofin-Sinar Technologies Inc. (NASDAQ:RSTI) one of the world’s leading developers and manufacturers of laser sources and laser-based solutions, confirmed today that its 2014 third quarter results for the period ended June 30, 2014, will be released on Thursday, August 7, 2014. Rofin-Sinar Technologies Inc. (NASDAQ:RSTI) ended the last trading day at $21.79. Company weekly volatility is calculated as 2.44%and price to cash ratio as 3.93. Rofin-Sinar Technologies Inc. (NASDAQ:RSTI) showed a weekly performance of -0.91%.

CarMax Inc. (NYSE:KMX) through its subsidiaries, operates as a retailer of used vehicles in the United States. It operates in two segments, CarMax Sales Operations and CarMax Auto Finance. KMX has a PE ratio of 22.0. Currently there are 8 analysts that rate CarMax a buy, no analysts rate it a sell, and 3 rate it a hold. CarMax Inc. (NYSE:KMX) shares increased 2.36% in last trading session and ended the day on $49.96. KMX Gross Margin is 13.10% and its return on assets is 4.50%. CarMax Inc. (NYSE:KMX) quarterly performance is 11.37%.